
    
      The maximal duration of the study participation for patients was 41 weeks and one day, split
      in:

        -  a 2-week screening period,

        -  a 39-week treatment period: 3 treatment periods of 13 weeks with a crossover alternative
           regimen, including a dose adjustment period of 1 week at the beginning of each period
           (sequence1: insulin glulisine, then insulin aspart, then insulin lispro; sequence2:
           insulin aspart, then insulin lispro, then insulin glulisine; sequence 3: insulin lispro,
           then insulin glulisine, then insulin aspart)

        -  and a follow-up period of 24 hours.
    
  